151 related articles for article (PubMed ID: 26376274)
1. "Excess Mortality" and Colistin-Tigecycline for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia.
Poulakou G; Bassetti M; Tsiodras S
Crit Care Med; 2015 Oct; 43(10):e470-1. PubMed ID: 26376274
[No Abstract] [Full Text] [Related]
2. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
[TBL] [Abstract][Full Text] [Related]
3. Appropriate Tigecycline Use for Extensively Drug-Resistant Infections: The Standard Dose May Not Be Enough!
De Pascale G; Antonelli M
Crit Care Med; 2015 Nov; 43(11):e533-4. PubMed ID: 26468725
[No Abstract] [Full Text] [Related]
4. Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?
Spellberg B; Bonomo RA
Crit Care Med; 2015 Jun; 43(6):1332-4. PubMed ID: 25978159
[No Abstract] [Full Text] [Related]
5. Mortality and Extensively Drug Resistance: Drugs or Methods? That Is the Question!
Corona A
Crit Care Med; 2015 Nov; 43(11):e538. PubMed ID: 26468731
[No Abstract] [Full Text] [Related]
6. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
8. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia.
Khawcharoenporn T; Pruetpongpun N; Tiamsak P; Rutchanawech S; Mundy LM; Apisarnthanarak A
Int J Antimicrob Agents; 2014 Apr; 43(4):378-82. PubMed ID: 24613422
[TBL] [Abstract][Full Text] [Related]
9. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections.
Ku K; Pogue JM; Moshos J; Bheemreddy S; Wang Y; Bhargava A; Campbell M; Khandker N; Lephart PR; Chopra T; Hayakawa K; Martin ET; Abreu-Lanfranco O; Dhar S; Kaye KS; Marchaim D
Am J Infect Control; 2012 Dec; 40(10):983-7. PubMed ID: 22440526
[TBL] [Abstract][Full Text] [Related]
10. Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors.
Park GE; Kang CI; Cha MK; Cho SY; Seok H; Lee JH; Kim JY; Ha YE; Chung DR; Peck KR; Lee NY; Song JH
Int J Infect Dis; 2017 Sep; 62():26-31. PubMed ID: 28676346
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii.
Kwon SH; Ahn HL; Han OY; La HO
Biol Pharm Bull; 2014; 37(3):340-6. PubMed ID: 24583855
[TBL] [Abstract][Full Text] [Related]
12. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
[TBL] [Abstract][Full Text] [Related]
13. Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.
Chaari A; Pham T; Mnif B; Chtara K; Medhioub F; Baccouche N; Bahloul M; Hammami A; Bouaziz M
Intensive Care Med; 2015 Nov; 41(11):2018-9. PubMed ID: 26264246
[No Abstract] [Full Text] [Related]
14. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
[TBL] [Abstract][Full Text] [Related]
15. Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain.
Merino M; Poza M; Roca I; Barba MJ; Sousa MD; Vila J; Bou G
Microb Drug Resist; 2014 Aug; 20(4):259-63. PubMed ID: 24328852
[TBL] [Abstract][Full Text] [Related]
16. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
Amat T; Gutiérrez-Pizarraya A; Machuca I; Gracia-Ahufinger I; Pérez-Nadales E; Torre-Giménez Á; Garnacho-Montero J; Cisneros JM; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24(6):630-634. PubMed ID: 28970161
[TBL] [Abstract][Full Text] [Related]
17. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia.
Zeng J; Zhang L; Gao M; Wu J; Wu H; Chen J; Chen X; Tang W
Int J Infect Dis; 2017 Aug; 61():23-26. PubMed ID: 28572073
[TBL] [Abstract][Full Text] [Related]
18. Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period.
Jasemi S; Douraghi M; Adibhesami H; Zeraati H; Rahbar M; Boroumand MA; Aliramezani A; Ghourchian S; Mohammadzadeh M
Lett Appl Microbiol; 2016 Dec; 63(6):466-472. PubMed ID: 27626896
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp.
Moon SY; Peck KR; Chang HH; Kim SW; Heo ST; Son JS; Ryu SY; Moon C; Jung SI; Shin SY; Lee JA; Joung MK; Chung DR; Kang CI; Song JH
Microb Drug Resist; 2012 Dec; 18(6):562-6. PubMed ID: 22775562
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii.
Mutlu Yilmaz E; Sunbul M; Aksoy A; Yilmaz H; Guney AK; Guvenc T
Int J Antimicrob Agents; 2012 Oct; 40(4):332-6. PubMed ID: 22831842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
